Clinical trial in New Zealand to test oral medication for recurrent genital herpes prevention.

A clinical trial in New Zealand will test a new medication aimed at preventing recurrences of genital herpes, which affects 80% of the population. Targeting individuals aged 18-60 with recurrent herpes, the trial seeks to determine if the medication can stop HSV-2 from reactivating. If successful, the oral medication could be taken weekly or less often, providing a new treatment option. Participants may receive compensation for their involvement.

October 24, 2024
5 Articles

Further Reading